BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

7:12 PM
 | 
Jun 04, 2007
 |  BC Extra  |  Clinical News

Genentech updates Avastin NSCLC Phase III

DNA reported additional data from the Phase III AVAiL trial of Avastin bevacizumab plus gemcitabine and cisplatin to treat non-small cell lung cancer, which DNA said met the primary endpoint of progression-free survival in February....

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >